公司于近日收到持股 5%以上股东横琴鼎典及其一致行动人珠海横琴润汇易 出具的《简式权益变动报告书》。 现将具体情况公告如下： 一、本次权益变动的基本情况 证券代码：301130 证券简称：西点药业 公告编号：2025-072 吉林省西点药业科技发展股份有限公司 关于持股 5%以上股东及其一致行动人减持股份进展 暨权益变动的提示性公告 持股 5%以上股东横琴鼎典股权投资基金合伙企业（有限合伙）及其一致行动 人珠海横琴润汇易投资合伙企业（有限合伙）保证向本公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ●本次权益变动主体为持有吉林省西点药业科技发展股份有限公司（以下 简称"西点药业"或"公司"）5%以上股份的股东横琴鼎典股权投资基金合伙 企业（有限合伙）（以下简称"横琴鼎典"）及其一致行动人珠海横琴润汇易 投资合伙企业（有限合伙）（以下简称"珠海横琴润汇易"）通过集中竞价、 大宗交易方式减持股份，不触及要约收购； ● 本次权益变动后，横琴鼎典及其一致行动人珠海横琴润汇易合计持有公 司 7,649,396 ...

吉林省西点药业科技发展股份有限公司 简式权益变动报告书 上市公司名称：吉林省西点药业科技发展股份有限公司 信息披露义务人一：横琴鼎典股权投资基金合伙企业（有限合伙） 住所：珠海市横琴新区汇通三路 108 号办公 1114 信息披露义务人二：珠海横琴润汇易投资合伙企业（有限合伙） 住所：珠海市横琴琴朗道 151 号 1915 办公 股份变动性质：减少 签署日期：2025 年 11 月 3 日 - 1 - 股票上市地点：深圳证券交易所 公司股票简称：西点药业 公司股票代码：301130 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称《证券 法》）《上市公司收购管理办法》（以下简称《收购办法》）《公开发行证 券的公司信息披露内容与格式准则第 15 号—权益变动报告书》（以下简称《准 则第 15 号》）及相关的法律、法规和规范性文件编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《证券法》《收购办法》《准则第 15 号》的规定，本报告书已 全面披露信息义务人在吉林省西点药业科技发展股份有限公司（以下简称上 市公司或西点药业）拥有权益的股份变动情况。 截至本 ...

Company Overview and Development History - Xidian Pharmaceutical, founded in 1990, transitioned from a small drug trading company to the largest in Jilin Province by 1994 [2][3] - The company went public on the Shenzhen Stock Exchange's Growth Enterprise Market in 2022, with a reported revenue of CNY 256 million in 2024 [2][4] Key Milestones - Significant milestones include the establishment of Xidian Pharmaceutical in 2001, the launch of the "Ruixiangsu" project, and the company's listing in 2022 [3][4] - The company has focused on the research and development of "Ruixiangsu," a key product derived from the Longbai Ruixiang plant, leading to major breakthroughs in synthesis technology [3][4] Market Positioning and Strategy - Xidian Pharmaceutical positions itself in niche markets, focusing on chronic diseases prevalent among the elderly, with a strategy of "one core and two wings" [4][5] - The core product is "Ruixiangsu" capsules, complemented by unique products like "Fufang Tianshu Yao" and "Risperidone" [5][6] Performance and Growth Drivers - In 2024, the company reported a 13.71% increase in revenue, but a decline in net profit due to reduced government subsidies and rising raw material costs [6][7] - The increase in operating costs by CNY 15.69 million in 2024 was primarily due to the surge in traditional Chinese medicine prices [6][7] Future Profit Growth Drivers - Core product expansion and new indications for "Ruixiangsu" are expected to drive future profits [7][8] - The company plans to enhance its product pipeline through increased R&D investment, which rose by 17.52% in 2024 [8][11] Core Products and R&D Innovation - "Yiyuan Sheng" (Fufang Tianshu Yao) generated approximately CNY 112 million in revenue in 2024, accounting for 43.64% of total revenue [9][10] - "Risperidone" saw a significant revenue increase of 38.93%, contributing 40.62% to total revenue [10][11] R&D Focus and Strategy - The company emphasizes innovation through a dual strategy of "independent R&D and joint development," focusing on chronic diseases and blood-related conditions [11][12] - Ongoing research includes expanding the indications for "Ruixiangsu" to include conditions like diabetic complications and viral pneumonia [12][13] Future Strategic Planning - Xidian Pharmaceutical aims to deepen its existing market presence while selectively expanding into new therapeutic areas related to aging [14][15] - The company is transitioning to a dual-driven sales model, combining hospital and retail markets, and enhancing digital marketing efforts [16][17] Investor Relations and Market Concerns - The management views the current product structure as a competitive strength rather than a risk, with plans for diversification and product upgrades [17][18] - A cash dividend of CNY 2.6 per 10 shares is proposed, representing 49.39% of the net profit for 2024 [18][19] Market Valuation and Core Value - The company emphasizes its unique product advantages and strategic positioning in the aging population's healthcare needs [19][20] - Xidian Pharmaceutical holds 29 formulation varieties and 17 raw material drug registrations, establishing a solid foundation for future growth [20]

Core Insights - West Point Pharmaceuticals (301130.SZ) released its Q3 2025 report on October 28, 2025, indicating a total of 8 institutional investors holding shares, amounting to 18.83 million shares, which represents 24.62% of the total share capital [1] Institutional Holdings - The institutional investors include Dingdian Investment Management (Beijing) Co., Ltd., Zhuhai Hengqin Yanhe Health Technology Co., Ltd., and several others, with a total institutional holding percentage of 24.62% [1] - Compared to the previous quarter, the total institutional holding percentage decreased by 0.30 percentage points [1] Public Fund Holdings - One new public fund, Yimin Core Growth Mixed Fund, was disclosed this quarter, while 23 public funds were not disclosed compared to the previous quarter [1] - Notable funds that were not disclosed include Nuon An Multi-Strategy Mixed A, Everbright Baode Trust Quantitative Stock A, and others [1]

Group 1 - The core viewpoint of the news is that Xidun Pharmaceutical reported a decline in revenue and net profit for the third quarter of 2025 compared to the previous year [1] - For the first three quarters of 2025, the company's revenue was approximately 189 million yuan, representing a year-on-year decrease of 1.89% [1] - The net profit attributable to shareholders was about 33.15 million yuan, reflecting a year-on-year decrease of 2.7% [1] - The basic earnings per share were 0.4333 yuan, which is a decrease of 0.41% year-on-year [1] Group 2 - As of the report date, Xidun Pharmaceutical has a market capitalization of 2.4 billion yuan [2]

Core Insights - West Point Pharmaceuticals (301130) reported a decline in revenue and net profit for Q3 2025, indicating potential challenges in the company's financial performance [1] Financial Performance - The company achieved a revenue of 60.63 million yuan in Q3 2025, representing a year-on-year decrease of 4.68% [1] - The net profit for the same period was 8.20 million yuan, reflecting a year-on-year decline of 14.70% [1]

Group 1 - The core point of the article is that Xidun Pharmaceutical announced the convening of its 13th meeting of the 8th Board of Directors on October 27, 2025, to review the proposal for the Q3 2025 report [1] - For the first half of 2025, Xidun Pharmaceutical's revenue composition shows that pharmaceuticals accounted for 99.39% of total revenue, while other businesses contributed 0.61% [1] - As of the time of reporting, Xidun Pharmaceutical has a market capitalization of 2.4 billion yuan [2]

Core Insights - West Point Pharmaceutical (301130.SZ) reported a revenue of 189 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 1.89% [1] - The net profit attributable to shareholders of the listed company was 33.1464 million yuan, down 2.70% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 29.8086 million yuan, showing a year-on-year increase of 3.19% [1] - The basic earnings per share were 0.4333 yuan [1]

国泰海通证券股份有限公司 关于吉林省西点药业科技发展股份有限公司部分募集资金 投资项目调整内部投资结构的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 吉林省西点药业科技发展股份有限公司（以下简称"西点药业"或"公司"）的 保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司募集资金监管规 则》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监 管指引第 13 号——保荐业务》《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》等相关规定，对西点药业部分募集资金投资项目 调整内部投资结构事项进行了审慎核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意吉林省 西点药业科技发展股份有限公司首次公开发行股票注册的批复》（证监许可〔2022〕 5 号）同意注册，公司首次公开发行人民币普通股（A 股）股票 2,020.0986 万股， 每股面值 1 元，每股发行价格为人民币 22.55 元，募集资金总额为人民币 45,553.22 万元，扣除各类发行费用后实际募集资金净额为人民币 39,093 ...

为进一步优化资金配置，提高财务运营效率，满足公司及子公司生产经营和 业务发展需要，公司及子公司拟向银行申请总额度不超过人民币 2 亿元的综合授 信，授信期限最长不超过 5 年。综合授信额度，包括但不限于公司及子公司办理 长、短期贷款、贸易融资、银行承兑汇票、商业承兑汇票、贴现、保函、信用证 （含国内信用证）、保理（含国内买方保理）、外汇衍生品交易等业务。 本次银行授信是信用授信，无需担保。以上授信额度不等于公司实际融资金 额，具体融资金额将根据运营资金的实际需求和按照资金使用审批权限相关规定 来确定及分配。本次授信额度项下的实际贷款金额应在授信额度内以各合作银行 与公司及子公司实际发生的贷款金额为准，公司及子公司可根据实际情况在不同 银行间进行调整。 上述综合授信额度的申请期限自董事会审议通过之日起不超过 12 个月（含 12 个月），且在授权期限内可循环使用。根据《深圳证券交易所创业板股票上 市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 证券代码：301130 证券简称：西点药业 公告编号：2025-069 吉林省西点药业科技发展股份有限公司 关于公司及子公司向银行申请综合授信 ...